Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.

Abdelrahman H ElsayedXueyuan CaoAmit Kumar MitraHuiyun WuSusana RaimondiChristopher R Cogle Zeina A Al-Mansour Raul C Ribeiro Alan S Gamis Edward Anders Kolb Richard AplencTodd A AlonzoSoheil MeshinchiJeffrey E RubnitzStanley PoundsJatinder Kaur Lamba

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Patients with low-ACS10 score experienced significantly poor outcome when treated on standard regimen. Augmentation with either high-dose ara-C or GO addition improved outcome in low-ACS10 group. A polygenic ACS10 score can identify patients with unfavorable pharmacogenetic characteristics and offers a potential for an elective augmented therapy option.

Keyphrases

acute coronary syndrome
high dose
acute myeloid leukemia
low dose
soft tissue
genome wide
gene expression
stem cell transplantation
risk assessment
human health
climate change
acute lymphoblastic leukemia
replacement therapy
cell therapy
virtual reality
smoking cessation